



Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :

GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com

Tel. 0132-3242000

25th May, 2015

The Manager – Operations & Listing
The Department of Corporate Services - CRD

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street, Fort

Mumbai – 400001

BSE Scrip Code: 531207

Subject: Outcome of the Meeting of the Board of Directors

Dear Sir,

This is to inform you that in the meeting of the Board of Directors of the Company, held on 25th May 2015, following resolutions were passed:


1. The Board considered and approved the Audited Financial Results for the quarter and the year ended 31st March, 2015 as per Clause 41 of the Listing Agreement.
2. The Board took note of the Auditor Report as per Annexure VII of Clause 41 of the Listing Agreement as placed by the auditor of the company.
3. The Board formulated, and approved procedure on unpublished price sensitive information (UPSI) as per fair Code of Conduct under regulation 8 and Code of Conduct under regulation 9 of Prohibition of Insider Trading Regulation 2015 affected from 15th May 15 2015.

You are kindly requested to take the information on record.

Thanking you,

Sincerely,

For **Raymed Labs Ltd.**



Ajar Goyal
Managing Director

DIN: 02636418

Encl: as stated

Cc: **Delhi Stock Exchange Limited**
Uttar Pradesh Stock Exchange Limited
Ahmedabad Stock Exchange Limited
Jaipur Stock Exchange Limited

Life is Preciousand Raymed cares



Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :

GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com

Tel. 0132-3242000

Statement of Assets and Liabilities

Rs. in Lacs

Particulars	As at year end 31-03-2015	As at previous year end 31-03-2014
	Audited	Audited
A EQUITY AND LIABILITIES		
1 Shareholders' Funds		
(a) Share Capital	427.35	427.35
(b) Reserves and Surplus	-	-
(c) Money Received Against Share Warrants	-	-
Sub-total - Shareholders' Funds	427.35	427.35
2 Share Application Money Pending Allotment		
3 Minority Interest		
4 Non-Current Liabilities		
(a) Long-Term Borrowings		
(b) Deferred Tax Liabilities (net)		
(c) Other Long-Term Liabilities		
(d) Long-Term Provisions		
Sub-total - Non-Current Liabilities		
5 Current Liabilities		
(a) Short-Term Borrowings	199.60	196.16
(b) Trade Payables	-	-
(c) Other Current Liabilities	3.75	4.96
(d) Short-Term Provisions	-	-
Sub-total - Current Liabilities	203.35	201.12
TOTAL - EQUITY AND LIABILITIES	630.70	628.47
B ASSETS		
1 Non-Current Assets		
(a) Fixed Assets	20.20	20.20
(b) Goodwill on Consolidation	-	-
(c) Non-current Investments	-	-
(d) Deferred Tax Assets (net)	-	-
(e) Long-term Loans and Advances	-	-
(f) Other Non-current Assets	-	-
Sub-total - Non-Current Assets	20.20	20.20
2 Current Assets		
(a) Current Investments	-	-
(b) Inventories	-	-
(c) Trade Receivables	2.49	2.49
(d) Cash and Cash Equivalents	0.49	0.08
(e) Short-term Loans and Advances	-	-
(f) Other Current Assets	7.10	7.10
Sub-total - Current Assets	10.08	9.68
TOTAL - ASSETS	30.28	29.88
3 Profit and Loss Account	600.42	598.59
TOTAL APPLICATION OF FUNDS	630.70	628.47

For Raymed Labs Limited

Ajai Goyal

Ajai Goyal

Place: Saharanpur

Date: 25.05.2014

Life is Preciousand Raymed cares



Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :

GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com

Tel. 0132-3242000

Audited Financial Results for the Quarter & Year Ended March 31, 2015

PART I		Rs. in Lacs				
Particulars	3 Months Ended 31-03-2015	Preceding 3 Months Ended 31-12-2014	Corresponding 3 Months in the Previous Year Ended 31-03-2014	Current Year Ended 31-03-2015	Previous Year Ended 31-03-2014	
	Audited	Unaudited	Audited	Audited	Audited	
1 Income from Operations						
(a) Net Sales / Income from Operations (Net of excise duty)	-	-	-	-	-	
(b) Other Operating Income	-	-	-	-	-	
Total Income from Operations (net)	-	-	-	-	-	
2 Expenses						
(a) Cost of materials consumed	-	-	-	-	-	
(b) Purchase of stock-in-trade	-	-	-	-	-	
Changes in inventories of finished goods,						
(c) work-in-progress and stock-in-trade	-	-	-	-	-	
(d) Employee expenses & benefits	0.15	0.15	0.42	1.00	1.68	
(e) Depreciation and amortisation expense	-	-	-0.12	-	0.19	
(f) Other expenses	0.43	0.16	0.38	2.99	1.52	
Total Expenses	0.58	0.31	0.68	3.99	3.39	
3 Profit/(Loss) from Operations before other Income, Finance costs and Exceptional Items (1-2)	-0.58	-0.31	-0.68	-3.99	-3.39	
4 Other Income	0.54	0.54	0.54	2.16	2.13	
5 Profit/Loss from ordinary activities before finance costs and exceptional Items (3+4)	-0.04	0.23	-0.14	-1.83	-1.26	
6 Finance Costs	0.00	-	-	0.00	-	
7 Profit/Loss from ordinary activities after finance costs but before exceptional Items (5-6)	-0.04	0.23	-0.14	-1.83	-1.26	
8 Exceptional Items	-	-	3.49	-	3.66	
9 Profit/Loss from Ordinary Activities before tax (7-8)	-0.04	0.23	-3.64	-1.83	-4.92	
10 Tax Expense	-	-	-	-	-	
11 Net Profit/ Loss from Ordinary Activities after Tax (9-10)	-0.04	0.23	-3.64	-1.83	-4.92	
12 Extraordinary Item (net of tax expense)	-	-	-	-	-	
13 Net Profit/ Loss for the period (11-12)	-0.04	0.23	-3.64	-1.83	-4.92	
17 Paid up Equity Share Capital (Face Value Rs.10/- per share)	427.35	427.35	427.35	427.35	427.35	
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	
19 i Earning Per Share (before extraordinary items)	-0.00	0.01	-0.09	-0.04	-0.12	
19 ii Earning Per Share (after extraordinary items)	-0.00	0.01	-0.09	-0.04	-0.12	



Life is Preciousand Raymed cares



Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :

GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com

Tel. 0132-3242000

PART II					
Particulars	3 Months Ended 31-03-2015	Preceding 3 Months Ended 31-12-2014	Corresponding 3 Months in the Previous Year Ended 31-03-2014	Current Year Ended 31-03-2015	Previous Year Ended 31-03-2014
A PARTICULARS OF SHAREHOLDING					
1 Public Shareholding					
- Number of shares	30,61,450	30,61,450	30,61,450	30,61,450	30,61,450
- Percentage of shareholding	71.64%	71.64%	71.64%	71.64%	71.64%
2 Promoters and promoter group Shareholding					
a) Pledged/Encumbered					
- Number of shares	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a% of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
b) Non-encumbered					
- Number of Shares	12,12,050	12,12,050	12,12,050	12,12,050	12,12,050
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
- Percentage of shares (as a% of the total share capital of the company)	28.36%	28.36%	28.36%	28.36%	28.36%
B INVESTOR COMPLAINTS					
3 Months Ended (31/03/2015)					
Pending at the beginning of the quarter	NIL				
Received during the quarter	NIL				
Disposed of during the quarter	NIL				
Remaining unresolved at the end of the quarter	NIL				

Notes:

- The audited financial statements for the quarter and year ended on March 31, 2015 as reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 25, 2015. The information presented above is extracted from the financial statement.
- The figures of the last quarter of current and corresponding previous year are the balancing figures between the audited figures of the full financial year and published year to date figures upto the third quarter of the financial year.
- EPS has been calculated in accordance with AS-20 issued by ICAI.
- The Business of the Company falls under a single segment for the purpose of Accounting Standard As-17, issued by The Institute of Chartered Accountants of India.
- Previous period/year figures have been regrouped/rearranged, wherever found necessary.
- No investor complaints were pending in the beginning and end of the quarter ended March 2015.

For Raymed Labs Limited

Ajay Goyal

Ajay Goyal
Place: Saharanpur
Date: 25-05-2015

Life is Preciousand Raymed cares



A. KAY. MEHRA & CO.

CHARTERED ACCOUNTANTS

114 (Basement), Mall Road, Kingsway Camp,
Delhi-110009 (Near GTB Nagar Metro Station)
Tel No. : 011-32965997, 9891295255
E-mail : akmca1969@gmail.com
Website : www.akmca.in

Annexure VII of Clause 41

To
The Board of Directors
Raymed Labs Limited

We have audited the quarterly financial results of **Raymed Labs Limited** for the quarter Ended 31st March 2015 (date of the quarter end) and the year to date results for the period 1st April 2014 to 31st March 2015 attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per section 211(3C) of the Companies Act, 1956 or by the Institute of Chartered Accountants of India and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit/ loss and other financial information for the quarter ended 31st March 2015 as well as the year to date results for the period from 1st April 2014 to 31st March 2015

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For M/s A Kay Mehra & Co.
Chartered Accountants
FRN 050004C
Deepak Suneja
Deepak Suneja
Partner
M.No. 501957

Date: May 25, 2015
Place: New Delhi